Despite significant improvement in the treatment of HER2-positive metastatic breast cancer in recent years, breast cancer remains a leading cause of death among women in the United States. The American Cancer Society estimates that approximately 287,850 women will be diagnosed with invasive breast cancer in 2022 and that 43,250 women will die of the disease. Treatment has become increasingly individualized with the emergence of several novel therapies, offering improved options to patients who progress on first-line therapy. Other agents are in development targeting a larger subset of breast cancer patients with low expression of human epidermal growth factor receptor 2 (HER2). To help clinicians select appropriate treatments based on their patients’ individual characteristics, Rockpointe and the Potomac Center for Medical Education offer a free CME/ANCC, ABIM MOC-eligible activity to be presented in a series of live webinars at hospital grand rounds and oncology society chapter meetings. 05
Metastatic breast cancer (MBC) is typically more complex than other cancers, with poorer prognosis and lower overall survival rates, and is more likely to express human epidermal growth factor receptor 2 (HER2). HER2-positive breast cancer accounts for 20% of all breast cancer cases. A novel subset of breast cancer comprising patients with low HER2 expression (IHC 1 or 2) represents up to 40% of all metastatic breast cancer cases. Personalized Approaches to HER2-Positive Breast Cancer Treatment is an hour-long program designed to provide oncology clinicians with information on the most recent treatments for HER2-positive breast cancer, expert recommendations for treatment selection and sequencing, and guidance on identifying and treating HER2-positive patients with low HER2 expression. This activity is geared specifically toward oncologists, pathologists, nurses, and other clinicians involved in the treatment of patients with breast cancer.
Upcoming Dates and times for grand rounds sessions:
Monday, March 14, 2022
12:00 – 1:00 PM ET (11:00 – 12:00 PM CT / 9:00 – 10:00 AM PT)
Wednesday, March 16, 2022
1:00 – 2:00 PM ET (12:00 – 1:00 PM CT / 10:00 – 11:00 AM PT)
Hosted by Holy Cross Hospital
Wednesday, March 23, 2022
12:00 – 1:00 PM MT (2:00 – 3:00 PM ET / 11:00 – 12:00 PM PT)
Friday, April 1, 2022
12:00 – 1:00 PM ET (11:00 – 12:00 PM CT / 9:00 – 10:00 AM PT)
Wednesday, June 22, 2022
12:00 – 1:00 PM ET (11:00 – 12:00 PM CT / 9:00 – 10:00 AM PT)
Dates and times for chapter meeting sessions:
Thursday, March 24, 2022
5:30 – 6:30 PM ET (4:30 – 5:30 PM CT / 2:30 – 3:30 PM PT)
Thursday, April 21, 2022
8:30 – 9:30 PM ET (7:30 – 8:30 PM CT / 5:30 – 6:30 PM PT)
Thursday, June 2, 2022
6:30 – 7:30 PM ET (5:30 – 6:30 PM CT / 3:30 – 4:30 PM PT)
At the conclusion of this activity, participants should be able to:
- Assess the safety and efficacy of currently approved treatments for HER2-positive MBC.
- Develop patient-personalized treatment plans for patients with progressive HER2-positive MBC on the basis of patient and disease characteristics.
- Evaluate patients with breast cancer for HER2 expression level.
- Discuss emerging treatments in development for HER2 low expression MBC.
This program is CME, CNE and ABIM MOC-certified and qualifies the participant for 1 hour of credit. There is no fee for this activity, which is supported by educational grants from AstraZeneca, Daiichi Sankyo, and Seagen and is jointly provided by the Potomac Center for Medical Education (PCME) and Rockpointe. Nursing accreditation is provided by Amedco. Full accreditation information will be provided to participants prior to starting the course.
Through effective accredited continuing education, Rockpointe, a leader in educational programming with more than 26 years of experience, strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combatting the nation’s opioid and COVID-19 crises, recognizing issues with vaping, and utilizing technical advances in care. Sign up for Rockpointe’s CME course catalog and view a list of current educational opportunities, including on-demand webcourse offerings and live webinars, at www.rockpointe.com.
As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy & Medicine, which offers a daily look at legal, regulatory, and compliance issues affecting the pharmaceutical and device industry. Rockpointe also publishes Policy & Medicine Compliance Update, a monthly publication that provides a concise update on compliance issues facing the life science industry and goes in-depth into important cases, laws, and regulations in straightforward articles. At Rockpointe, education equals quality.
To register for a grand rounds session of Personalized Approaches to HER2-Positive Breast Cancer Treatment, click here. To register for a chapter meeting session, click here